Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial health, with a significant cash reserve and no debt. The share repurchase program reduced the share count by over 15%, which is positive for shareholder returns. The Q&A session revealed optimistic guidance on clinical trials, with management preparing for potential product launches and emphasizing strategic business development opportunities. Despite some unclear responses, the overall sentiment is positive due to the robust financial position, ongoing clinical execution, and strategic focus on late-stage pipeline developments.
Key Financial Performance
Net Loss Net loss of $170 million, with no year-over-year change or reasons for change mentioned.
Cash Utilization Cash utilization of about $200 million outside of the share repurchase program and other one-time events, with no year-over-year change or reasons for change mentioned.
Cash Balance $4.5 billion of cash as of June 30, 2025, with no debt and no year-over-year change or reasons for change mentioned.
Share Repurchase Program Completed $1.5 billion authorized share repurchase program as of June 2025, repurchasing just under 150 million shares at an average price of just over $10 per share, reducing share count by over 15%. No year-over-year change or reasons for change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IMVT-1402: Continued progress in developing a best-in-class anti-FcRn antibody. Focused on clinical execution, including the Graves study and other announced indications.
Brepocitinib: Registrational Dermatomyositis data expected soon, setting the stage for a commercial launch. Five registrational trials ongoing, with potential to redefine the standard of care for Dermatomyositis.
Mosliciguat: Pulmonary hypertension program with data expected in the second half of next year.
Commercial footprint expansion: Potential for a significantly larger commercial footprint in the coming years, starting with brepocitinib and expanding across the FcRn portfolio.
Share repurchase program: Completed a $1.5 billion share repurchase program, reducing share count by over 15%. Authorized an additional $500 million repurchase program.
Pipeline expansion: Meaningful expansion of the pipeline, including progress in brepocitinib and IMVT-1402 clinical trials.
LNP Litigation: Ongoing litigation with Moderna, Pfizer, and BioNTech, with significant developments expected in 2026. Summary judgment motions filed in the U.S. Moderna case.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
IMVT-1402 Clinical Execution: Challenges in clinical execution for IMVT-1402, including enrollment in the Graves' disease study and progressing other indications, could impact timelines and outcomes.
Brepocitinib Commercial Launch: The success of the brepocitinib commercial launch depends on the pivotal trial results for dermatomyositis, which carries inherent risks of trial failure or suboptimal outcomes.
LNP Litigation: Ongoing litigation with Moderna, Pfizer, and BioNTech presents legal and financial risks, including potential unfavorable rulings or prolonged legal battles.
Pipeline Expansion and Execution: Managing multiple registrational trials and proof-of-concept studies across the pipeline could strain resources and delay progress.
Share Repurchase Program: The $500 million share repurchase program could limit financial flexibility, especially if market conditions worsen or additional capital is required for operations.
Economic and Market Conditions: Volatility in market conditions could impact the company's financial performance and ability to execute strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
IMVT-1402 Development: Continued progress in developing IMVT-1402 as a best-in-class anti-FcRn antibody. Focus on clinical execution, including the Graves study enrollment and other announced indications.
Brepocitinib Data and Launch: Registrational Dermatomyositis data from brepocitinib expected in the second half of 2025. Potential commercial launch of brepocitinib in Dermatomyositis following positive data.
Pipeline Expansion: Multiple registrational trials ongoing for IMVT-1402 and Mosliciguat. Data for Mosliciguat in pulmonary hypertension expected in the second half of 2026.
Future Commercial Footprint: Potential for a significant commercial footprint in the next few years, starting with brepocitinib and expanding across the FcRn portfolio.
Brepocitinib in Dermatomyositis: VALOR study designed to establish brepocitinib as a standard of care for Dermatomyositis. Regulatory filing for use in Dermatomyositis expected after data release, with a potential launch in 2027.
LNP Litigation: Ongoing litigation with Moderna, Pfizer, and BioNTech. U.S. jury trial for Moderna case scheduled for March 2026, with major international hearings expected in the first half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program Completion: The company completed a $1.5 billion authorized share repurchase program as of June 2025, repurchasing just under 150 million shares at an average price of just over $10 per share, reducing the share count by over 15%.
New Share Repurchase Authorization: Following the completion of the previous program, the Board authorized an additional $500 million share repurchase program, which will be evaluated for opportunistic use depending on market conditions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about how much data we could get at the time of your top line for DM? Assuming the data is positive, how far are you from filing for approval?
A:The expectation is to have top line, all key secondaries, and major safety data to share approximately contemporaneously with the data. Filing is guided for the very beginning of next year, with no unusual gating factors beyond normal NDA prep activities.
Q:What is the rationale for testing a lower dose in the second Graves' trial?
A:The rationale is to ensure FDA approval by advocating for a minimally efficacious dose. The trial design aims to meet FDA requirements without issues.
Q:How is a flare defined in the DM trial, and how does the flare get treated on TIF?
A:The trial has an active protocol for managing patients as they progress. Definitions for rescue therapy vary depending on whether the investigator calls it a rescue or simply treats the patient. The goal is to identify patients who are flaring and worsening.
Q:What impact could an imbalance in steroid elimination have on the primary endpoint of TIF between the two arms?
A:If steroid doses were much higher in the placebo arm than the drug arm, it could result in better outcomes for the placebo arm. However, the trial is designed to maximize the opportunity for accurate results.
Q:What does clinically meaningful outcomes look like for the upcoming Graves remission data?
A:Any amount of meaningful remission would be practice-changing for Graves' patients. Even 10% remission would be extraordinary, as these patients are typically on lifelong ATD therapy.
Q:What is the outlook for business development (BD) and the type of deals you are most interested in?
A:The company remains opportunistic, focusing on potentially transformational late-stage opportunities. The market is attractive for asset hunting due to uncertainty and restructuring in big pharma.
Q:What is the typical steroid dose for a flare-up in the DM trial, and is it defined in the protocol?
A:The steroid dose for a flare-up is not strictly defined in the protocol and is left to the investigator's discretion. The goal is to treat rescue therapy consistently across different doctors.
Q:Is the China market of interest for your BD strategy, and what is your take on the competition and quality of assets there?
A:The company is agnostic and has been exploring opportunities in China. The market has high-quality drug candidates, and the lead among programs has significantly shortened.
Q:What is the bar for efficacy in the DM trial, and what are the expectations for the 15-milligram dose?
A:The bar for efficacy is a simple statistically significant trial on TIS. The 15-milligram dose is included for regulatory reasons, and the primary focus is on the 30-milligram dose.
Q:Can you provide an update on enrollment for the 1401 and 1402 registration studies?
A:All 1401 trials are fully enrolled, and enrollment for 1402 trials is progressing well. The company is on track to meet publicly stated timelines.
Q:What do you hope to report at ATA for the Graves' disease program?
A:The goal is to highlight the transformative potential of the drug, showing that it can achieve remission for patients who would otherwise be on lifelong medication.
Q:What is the road map for brepocitinib in NIU pivotal development and potential filing?
A:The trial is progressing well, with data expected in the first half of 2027. The company plans to file an sNDA shortly after data readout, with a shorter review timeline than the original NDA.
Q:How informative is prior data with JAK1 on TIS for brepocitinib?
A:The prior data is considered highly informative, showing consistent benefit on both muscle and skin. However, placebo-controlled data is needed for approval.
Q:How is the company preparing for a potential launch in DM?
A:The company is engaging with the physician community and building a strong reputation. Preparations will intensify once Phase III data is available.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how flares are defined and treated in the DM trial, as well as the exact steroid doses used during flare-ups. They also did not clarify the expectations for the 15-milligram dose in the DM trial, stating it was included for regulatory reasons without elaborating on its potential efficacy.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Capital LLC
Co LLC
Co Research
Corinne Johnson
Director Griffin
Division Douglas
Division ET
Division Prakhar
Division Reed
Division Samuel
Division Wolfe
Division Yatin
Division Yuchen
Douglas Dylan
Dylan Tsao
ET Gline
ET day
Evan Slutsky
Griffin Vice
Group Inc
HC Wainwright
Inc Research
Jefferies LLC
Johnson Goldman
LLC Research
Lut Ming
Ming Cheng
Partners LLC
President Special
Projects Corinne
Research Division
ROIV Transcript
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Neutral5-29
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
ROIV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
